Trial Radar
Sign in

NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease

NCT07184944

RecruitingPhase 3

Sponsor: Sanofi

Conditions: Crohn's Disease

Interventions: Duvakitug, Placebo

Countries: United States, Canada, Georgia, Japan, Moldova, South Africa, Ukraine

This is a multicenter, randomized, double-blind, placebo-controlled, maintenance, Phase 3 study to evaluate the efficacy and safety of duvakitug in participants with moderately to severely active Crohn's Disease (CD). Study details include: The study duration may be up to 286 weeks including: * 40-week Pivotal Maintenance Sub-Study * 240-week Open-Label Extension (OLE) Sub-Study * 45-day Follow-Up visit Note: For the participants who do not enroll into OLE Sub-Study, the duration will be up to 46 weeks, including the 40-week maintenance period and a 45-day follow-up visit. The treatment duration may be up to 280 weeks including: * 40 weeks in the Pivotal Maintenance Sub-Study * 240 weeks in OLE Sub-Study The total number of on-site visits will be up to 43: - 21 visits in the Pivotal Maintenance Sub-Study - 22 visits in the OLE Sub-Study

Eligibility overview

Sex: ALL

Age: 16 Years to 80 Years

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria
Inclusion Criteria:

* Participants aged ≥18 and ≤80 years of age at Baseline. (Where locally permissible, participants 16 to \<18 years of age who meet the definition of Tanner stage 5 for development)
* Pivotal Maintenance Sub-Study: Participants who achieved clinical response and completed endoscopy at the end of STARSCAPE-1
* OLE Sub-Study: Participants who complete the Pivotal Maintenance Sub-Study or participation in the TV48574-IMM-20038 Study

Exclusion Criteria:

* Participants with medical or compliance conditions that are deemed unsuitable for the study by the investigator
* Participants with a known hypersensitivity to duvakitug that makes the participant unsuitable for the study by the investigator

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial
Locations (35)
  • Colorado Springs, Colorado, United States
  • Kissimmee, Florida, United States
  • Miami, Florida, United States
  • Tampa, Florida, United States
  • New Albany, Indiana, United States
  • Baton Rouge, Louisiana, United States
  • Mandeville, Louisiana, United States
  • St Louis, Missouri, United States
  • Maspeth, New York, United States
  • New York, New York, United States
  • New York, New York, United States
  • New York, New York, United States
  • Chapel Hill, North Carolina, United States
  • Fayetteville, North Carolina, United States
  • Columbus, Ohio, United States
  • Columbus, Ohio, United States
  • Westlake, Ohio, United States
  • Philadelphia, Pennsylvania, United States
  • Lubbock, Texas, United States
  • San Antonio, Texas, United States
  • Tyler, Texas, United States
  • Wyoming, Wyoming, United States
  • Hamilton, Canada
  • Toronto, Canada
  • Tbilisi, Georgia
  • Tbilisi, Georgia
  • Tbilisi, Georgia
  • Tbilisi, Georgia
  • Tsu, Japan
  • Chisinau, Moldova
  • + 5 more on CT.gov